



Atty. Dkt. No. 029488-0111

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruno DE LIGNIERES
Title: TREATMENT OF MASTALGIA
WITH 4-HYDROXY
TAMOXIFEN
Appl. No.: 10/734,640
Filing Date: 12/15/2003
Examiner: U. Ramachandran
Art Unit: 1617
Confirmation 9061
Number:

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Your Petitioner, Laboratoires Besins International SA, having its principal place of business at 13, rue Perier, Montrouge, 92120 France, represents that it is the owner of the entire right, title, and interest in and to U.S. Patent Application Serial No. 10/734,640 filed 12/15/2003, by virtue of an Assignment filed and recorded on March 3, 2005 on Reel/Frame 016118/0325, in the United States Patent and Trademark Office, a copy of the abstract of title of which is attached hereto as APPENDIX A. Further, your Petitioner represents that it is the owner of U.S. Patent Application No. 10/734,638 filed December 15, 2003, by virtue of an Assignment filed and recorded on January 17, 2006 on Reel/Frame 017199/0967, in the United States Patent and Trademark Office, a copy of the abstract of title of which is attached hereto as APPENDIX B.

Your Petitioner, Laboratoires Besins International SA, hereby disclaims the terminal part of the term of any patent granted on U.S. Patent Application 10/734,640 which

02/22/2008 HNGUYEN1 00000070 10734640

02 FC:1814

130.00 0P

would extend beyond the full statutory term, as shortened by any terminal disclaimer, of any patent granted on U.S. Patent Application 10/734,638, and hereby agrees that any patent so granted on U.S. Patent Application 10/734,640 shall be enforceable only for and during such period that the legal title to any patent granted on U.S. Patent Application 10/734,638 shall be the same as the legal title to any patent granted on U.S. Patent Application 10/734,640, this agreement to run with any patent granted on U.S. Patent Application 10/734,640 and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on U.S. Patent Application 10/734,640, prior to the full statutory term of any patent granted on U.S. Patent Application 10/734,638 as defined in 35 U.S.C. §§154-156 and 173, in the event that any patent granted on U.S. Patent Application 10/734,638 expires for failure to pay a maintenance fee, is held unenforceable or is found invalid in a final judgment by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims canceled by a reexamination certificate or as a result of an interference proceeding, or is otherwise not deemed to provide the rights conveyed by 35 USC §154, prior to its full statutory term as defined in 35 USC §§154-156 and 173, except for the separation of legal title stated above. Further, Petitioner does not disclaim any terminal part of a patent granted on U.S. Patent Application 10/734,640 that would extend beyond the present termination of any patent granted on U.S. Patent Application 10/734,638, in the event that such present term is extended by virtue of compliance with the conditions for term extension of any present or future patent term extension provisions of the patent law, including but not limited to 35 U.S.C. §§155, 155A or 156, and without waiving Petitioner's right to extend the term of a patent granted on U.S. Patent Application 10/734,640 to the extent provided by law, including but not limited to 35 U.S.C. §§155, 155A or 156.

The undersigned, being the Attorney of Record for U.S. Patent Application 10/734,640, and duly authorized to act on behalf of Petitioner, certifies that she has reviewed the Patent Assignment Abstracts of Title attached as APPENDICES A and B, and to the best of her knowledge and belief, legal title to U.S. Patent Application 10/734,640 and any patent granted on U.S. Patent Application 10/734,638 rests with Petitioners, Laboratoires Besins

International SA. The undersigned declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing therefrom.

Respectfully submitted,

Date February 21, 2008

By Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 295-4094
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff
Attorney for Applicant
Registration No. 37,288

APPENDIX A

10/734,640 Treatment of mastalgia with 4-hydroxy tamoxifen

02-20-
2008::14:03:48

Patent Assignment Abstract of Title

Total Assignments: 1**Application #:** 10734640**Filing Dt:** 12/15/2003**Patent #:** NONE**Issue Dt:****PCT #:** NONE**Publication #:** US20050032909**Pub Dt:** 02/10/2005**Inventors:** Bruno de Lignieres, Gabrielle Elisabeth Brink de Lignieres**Title:** Treatment of mastalgia with 4-hydroxy tamoxifen**Assignment: 1****Reel/Frame:** 016118 / 0325**Received:** 01/06/2005**Recorded:** 01/03/2005**Mailed:** 06/10/2005 ~**Pages:** 3**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignor:** DE LIGNIERES, GABRIELLE ELISABETH BRINK LEGAL REPRESENTATIVE
FOR BRUNO DE LIGNIERES (DECEASED)**Exec Dt:** 11/23/2004**Assignee:** LABORATORIES BESINS INTERNATIONAL
SA, 13, RUE PERIER
92120, MONTRouGE, FRANCE**Correspondent:** STEPHEN A. BENT
FOLEY & LARDNER LLP
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5143

Search Results as of: 02/20/2008 14:03:41 PM

Disclaimer:**Assignment information on the assignment database reflects assignment documents that have been actually recorded.****If the assignment for a patent was not recorded, the name of the assignee on the patent application publication or patent may be different.****If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 571-272-3350**

Close Window

APPENDIX B

10/734,638 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

02-20-
2008::14:02:04

Patent Assignment Abstract of Title

Total Assignments: 1**Application #:** 10734638**Filing Dt:** 12/15/2003**Patent #:** NONE**Issue Dt:****PCT #:** NONE**Publication #:** US20050031695**Pub Dt:** 02/10/2005**Inventors:** Philippe Rouanet, Dominique Salin Drouin, Jacques Weppierre**Title:** Prevention and treatment of breast cancer with 4-hydroxy tamoxifen**Assignment: 1****Reel/Frame:** 017199 / 0967**Received:** 01/17/2006**Recorded:** 01/17/2006**Mailed:** 02/22/2006**Pages:** 3**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignors:** ROUANET, PHILIPPE**Exec Dt:** 12/28/2005

DROUIN, DOMINIQUE SALIN

Exec Dt: 12/07/2005

WEPIERRE, JACQUES

Exec Dt: 11/13/2005**Assignee:** LABORATOIRES BESINS INTERNATIONAL SA

13, RUE PERIER

MONTROUGE 92120, FRANCE

Correspondent: STEPHEN A. BENT

FOLEY & LARDNER LLP

WASHINGTON HARBOUR

3000 K STREET, N.W., SUITE 500

WASHINGTON, DC 20007-5143

Search Results as of: 02/20/2008 14:01:56 PM

Disclaimer:**Assignment information on the assignment database reflects assignment documents that have been actually recorded.****If the assignment for a patent was not recorded, the name of the assignee on the patent application publication or patent may be different.****If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 571-272-3350**

Close Window